Title |
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
|
---|---|
Published in |
PharmacoEconomics - Open, September 2019
|
DOI | 10.1007/s41669-019-00178-7 |
Pubmed ID | |
Authors |
Herbert H. Loong, Carlos K. H. Wong, Linda Kam Suet Leung, Praveen Dhankhar, Ralph P. Insinga, Sheenu Chandwani, Danny C. Hsu, Mary Y. K. Lee, Min Huang, James Pellissier, Akanksha Rai, Monika Achra, Seng Chuen Tan |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Hong Kong | 2 | 25% |
Japan | 1 | 13% |
United States | 1 | 13% |
New Zealand | 1 | 13% |
Indonesia | 1 | 13% |
Unknown | 2 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 50% |
Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Scientists | 1 | 13% |
Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 46 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 24% |
Other | 5 | 11% |
Student > Master | 5 | 11% |
Student > Bachelor | 3 | 7% |
Lecturer | 1 | 2% |
Other | 3 | 7% |
Unknown | 18 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 35% |
Nursing and Health Professions | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Agricultural and Biological Sciences | 1 | 2% |
Environmental Science | 1 | 2% |
Other | 2 | 4% |
Unknown | 21 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2019.
All research outputs
#5,625,481
of 23,163,378 outputs
Outputs from PharmacoEconomics - Open
#96
of 333 outputs
Outputs of similar age
#98,689
of 342,607 outputs
Outputs of similar age from PharmacoEconomics - Open
#3
of 15 outputs
Altmetric has tracked 23,163,378 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 333 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.